Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Cannita · SciRah

Researcher profile · Semantic Scholar

K. Cannita

Share profile

K. Cannita — researcher profile on SciRah

h-index: 26
Works: 146
Citations: 2,938

Most-cited papers

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
A. Cortellini, M. Bersanelli, S. Buti, K. Cannita +41 more
2019Journal of Immunotherapy for Cancer385 citations Open access
Semantic Scholar
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
A. Cortellini, R. Chiari, B. Ricciuti, G. Metro +31 more
2019Clinical Lung Cancer167 citations
Semantic Scholar
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
A. Cortellini, S. Buti, D. Santini, F. Perrone +41 more
2019The Oncologist167 citations Open access
Semantic Scholar
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
A. Cortellini, M. di Maio, O. Nigro, A. Leonetti +57 more
2021Journal for ImmunoTherapy of Cancer151 citations Open access
Semantic Scholar
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
A. Cortellini, M. Bersanelli, D. Santini, S. Buti +34 more
2020European Journal of Cancer112 citations
Semantic Scholar
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
A. Cortellini, F. Bozzetti, P. Palumbo, D. Brocco +16 more
2020Scientific Reports86 citations Open access
Semantic Scholar
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
A. Cortellini, A. Friedlaender, G. Banna, G. Porzio +67 more
2020Clinical Lung Cancer79 citations Open access
Semantic Scholar
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
A. Cortellini, A. D'Alessio, S. Cleary, S. Buti +54 more
2023Clinical Cancer Research70 citations Open access
Semantic Scholar
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
A. Cortellini, L. Verna, G. Porzio, F. Bozzetti +7 more
2019Thoracic Cancer64 citations Open access
Semantic Scholar
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
P. Vici, L. Pizzuti, A. Michelotti, I. Sperduti +44 more
2017OncoTarget61 citations Open access
Semantic Scholar
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
A. Fabi, D. Alesini, E. Valle, L. Moscetti +26 more
2018Breast53 citations
Semantic Scholar
Single‐institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non‐small cell lung cancer patients treated with first‐line chemotherapy
A. Cortellini, P. Palumbo, G. Porzio, L. Verna +6 more
2018Thoracic Cancer49 citations Open access
Semantic Scholar
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
A. Cortellini, A. De Giglio, K. Cannita, D. Cortinovis +47 more
2021Thoracic Cancer48 citations Open access
Semantic Scholar
Breast cancer and psychological resilience among young women
D. Di Giacomo, K. Cannita, J. Ranieri, V. Cocciolone +2 more
201637 citations
Semantic Scholar
Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
Veronica Zelli, Chiara Compagnoni, K. Cannita, R. Capelli +5 more
2020High-Throughput34 citations Open access
Semantic Scholar
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
A. Grassadonia, P. Di Marino, C. Ficorella, A. Cortellini +12 more
2019Journal of Cancer32 citations Open access
Semantic Scholar
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
A. Cortellini, K. Cannita, M. Tiseo, D. Cortinovis +48 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
S. Buti, M. Bersanelli, F. Perrone, S. Bracarda +57 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
A. Fabi, D. Giannarelli, L. Moscetti, D. Santini +15 more
2017Future Oncology28 citations
Semantic Scholar
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence
E. Krasniqi, L. Pizzuti, Giacomo Barchiesi, D. Sergi +64 more
2020Journal of Cellular Physiology27 citations
Semantic Scholar
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A. Cortellini, A. Leonetti, A. Catino, P. Pizzutillo +33 more
2019Clinical and Translational Oncology25 citations Open access
Semantic Scholar
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
G. Bruera, K. Cannita, A. Tessitore, A. Russo +3 more
2015Critical reviews in oncology/hematology25 citations Open access
Semantic Scholar
Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes
Veronica Zelli, Chiara Compagnoni, R. Capelli, K. Cannita +6 more
2020Journal of Personalized Medicine24 citations Open access
Semantic Scholar
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
L. Pizzuti, A. Giordano, A. Michelotti, M. Mazzotta +64 more
2018Journal of Cellular Physiology24 citations Open access
Semantic Scholar
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience
A. Parisi, E. Palluzzi, A. Cortellini, T. Sidoni +5 more
2019Clinical and Translational Oncology22 citations
Semantic Scholar
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study
A. Fabi, M. de Laurentiis, M. Caruso, E. Valle +24 more
2017OncoTarget21 citations Open access
Semantic Scholar
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
A. Parisi, A. Cortellini, K. Cannita, O. Venditti +35 more
2020Cancers19 citations Open access
Semantic Scholar
Psychological impact of clinical treatment after breast cancer diagnosis in younger patients (38–50 age range): An explorative 3-year observational study
D. Di Giacomo, J. Ranieri, E. Perilli, K. Cannita +2 more
2019Neurology Psychiatry and Brain Research17 citations Open access
Semantic Scholar
Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective.
D. Di Giacomo, J. Ranieri, Federica Guerra, E. Perilli +4 more
2019Rivista di psichiatria17 citations Open access
Semantic Scholar
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
A. Cortellini, M. Bersanelli, S. Buti, E. Gambale +19 more
2018Immunotherapy16 citations Open access
Semantic Scholar
Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
A. Cortellini, L. Verna, K. Cannita, Luca Napoleoni +3 more
2017Indian Journal of Palliative Care16 citations Open access
Semantic Scholar
Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
A. Irelli, Sofia Chiatamone Ranieri, Daniela Di Giacomo, S. Malatesta +4 more
2023Cancers15 citations Open access
Semantic Scholar
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.
A. Irelli, V. Cocciolone, K. Cannita, L. Zugaro +6 more
2016Bone15 citations
Semantic Scholar
What Is Known about Theragnostic Strategies in Colorectal Cancer
A. Parisi, G. Porzio, Fanny Pulcini, K. Cannita +3 more
2021Biomedicines14 citations Open access
Semantic Scholar
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2013BioMed Research International14 citations Open access
Semantic Scholar
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
M. Bersanelli, E. Lattanzi, N. D'Abbiero, S. Buti +21 more
2019Biomedical Reports13 citations Open access
Semantic Scholar
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study
A. Parisi, A. Cortellini, Michela Roberto, O. Venditti +17 more
2019Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
L. Pizzuti, E. Krasniqi, I. Sperduti, M. Barba +76 more
2021Therapeutic Advances in Medical Oncology12 citations Open access
Semantic Scholar
Emotional “Patient-Oriented” Support in Young Patients With I–II Stage Breast Cancer: Pilot Study
D. Di Giacomo, J. Ranieri, E. Donatucci, E. Perilli +3 more
2018Frontiers in Psychology12 citations Open access
Semantic Scholar
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2014International Journal of Oncology12 citations Open access
Semantic Scholar
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
A. Parisi, G. Porzio, K. Cannita, O. Venditti +35 more
2021Clinical colorectal cancer11 citations
Semantic Scholar
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
A. Parisi, A. Cortellini, K. Cannita, M. Bersanelli +1 more
2019Case Reports in Oncological Medicine11 citations Open access
Semantic Scholar
Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
G. Bruera, K. Cannita, A. Giordano, R. Manetta +7 more
2014BioMed Research International11 citations Open access
Semantic Scholar
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2013International Journal of Oncology11 citations Open access
Semantic Scholar
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
F. S. Di Lisa, E. Krasniqi, L. Pizzuti, M. Barba +80 more
2023Frontiers in Oncology10 citations Open access
Semantic Scholar
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
Veronica Zelli, A. Parisi, L. Patruno, K. Cannita +6 more
2022Frontiers in Oncology10 citations Open access
Semantic Scholar
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
E. Krasniqi, L. Pizzuti, M. Valerio, E. Capomolla +29 more
2021International Journal of Medical Sciences10 citations Open access
Semantic Scholar
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma.
A. Cortellini, S. Buti, M. Bersanelli, K. Cannita +11 more
2020Current Urology10 citations Open access
Semantic Scholar
Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
A. Irelli, G. Bruera, K. Cannita, Eleonora Palluzzi +4 more
2014BioMed Research International10 citations Open access
Semantic Scholar
Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception
A. Irelli, J. Ranieri, M. Sirufo, Francesca De Pietro +4 more
2022Journal of Clinical Medicine9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Ficorella×43
Invite
C. Ficorella — researcher profile on SciRah
A. Cortellini×24
Invite
A. Cortellini — researcher profile on SciRah
G. Porzio×21
Invite
G. Porzio — researcher profile on SciRah
D. Santini×19
Invite
D. Santini — researcher profile on SciRah

×18

Invite

M. De Tursi — researcher profile on SciRah

Invite

F. Zoratto — researcher profile on SciRah

Invite

N. Tinari — researcher profile on SciRah

P. Marchetti×15

Invite

P. Marchetti — researcher profile on SciRah

Invite

R. Berardi — researcher profile on SciRah

Invite

A. Parisi — researcher profile on SciRah

M. Bersanelli×11

Invite

M. Bersanelli — researcher profile on SciRah

Invite

R. Giusti — researcher profile on SciRah